Allergan Inc. (AGN)
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Allergan Inc. (AGN)
36 articles
Filter by:
Latest Articles Most commented on articlesMost frequent authors on AGN
- SA Editor Miriam Metzinger(31)
- Mike Havrilla(3)
- Alan Brochstein(3)
- Centient Biotech Investor(3)
- theflyonthewall.com (2)
Most popular authors
(tracked in watchlists)
- Bespoke Investment Group(665)
- SA Editor Eli Hoffmann(412)
- Andrew Wilkinson(398)
- Market Folly(287)
- Alan Brochstein(221)
Most commented on authors
- Updated FDA Decision Calendar: Five Decisions Before Year-End
- Hedge Fund Tracking: Bruce Kovner's Caxton Associates, Q3 2008
- Johnson & Johnson Steals Mentor Corp.: Who's Next?
- Weekly FDA Calendar Update
- Rigel Pharmaceuticals: Biotech Crisis or Opportunity?
- Earnings Preview: Allergan
- Friday Options Update: MSFT, HBC, DWA, AGN, XLF, C, MS and VIX
- Industry Profile: Cosmetic and Reconstructive Medicine
- Summer Surge for Pharma Powers IHE, but Concerns Remain
- Allergan: When Deals Get Ugly
- Earnings Preview: Allergan
- Roche and Allergan Victorious Over Apotex in Acular LS Dispute
- Credit Suisse Healthier 15: Investors Get the Skinny on Fat Fighters
- Will Wal-Mart Heat Up Chile? Fast Money (6/17/08)
- Wrinkle in Allergan’s Forecast
- Pfizer Should Buy Amgen or Wyeth - Credit Suisse
- Wall Street Breakfast: Must-Know News
- Allergan Drops Unnecessarily on FDA BOTOX Review
- 7 Healthcare Stocks for a Sick Market
- Allergan Acquires Esprit for $370 Million
- Best, Worst Performing Stocks Since the Market Top On 7/16
- Botox Not Just For Wrinkles: Time to Reconsider Allergan
- Recent Earnings Strength Tied to International Exposure
- The Investable Universe of Aesthetic Healthcare Stocks
- Barron's Baby Boomer Stocks
- Biotech Day in Review: Allergan Expands Obesity Franchise
- What is Wrong with Allergan?
- Biotech Week-in-Review: Genentech, Amgen Take a Toll on Biotech
- Report From JPMorgan's HealthCare Conference: The Spinal Business Is Hot
- FDA Approvable Letters for New River Pharmaceuticals, Shire, Allergan and Perrigo
- Missed Allergan? There's Still Syneron.
- FDA Breast Implant News Boosts Allergan, Mentor Shares
- Pharma IPO: Highlights from Obagi Medical's S-1 Filing
- What the Botox Boom Means for Allergan (AGN)
- Who Gains, Who Loses From the Bausch & Lomb Recall? (BOL, JNJ, COO, ACL, AGN, EYE, CTAC)
-
BusinessWeek Recommends Elizabeth Arden (RDEN)
on Jan 22, 2006
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »